超级牛股，明日复牌！网友：看看是否还是老大

Core Viewpoint - The article discusses the upcoming resumption of trading for the stock of HeFu China, which has experienced significant price volatility and a substantial increase in stock price over a short period, raising concerns about market speculation and potential risks associated with its valuation [2][5][10]. Group 1: Stock Resumption and Trading Details - HeFu China will resume trading on November 20, 2025, after completing a review of its stock trading activities [2][3]. - The stock has seen a remarkable increase of 256.29% from October 28 to November 14, with a closing price of 23.8 yuan per share and a total market capitalization of 9.5 billion yuan before the suspension [5]. Group 2: Company Performance and Financials - For the first three quarters of 2025, HeFu China reported a revenue of 549 million yuan, a year-on-year decline of 22.8%, and a net loss of 12 million yuan, indicating a shift from profit to loss [10]. - The decline in revenue and profit is attributed to changes in the domestic macroeconomic environment and price reductions due to centralized procurement policies in the medical industry [10]. Group 3: Market Sentiment and Risks - HeFu China has indicated that there are no undisclosed significant matters affecting its stock price, but it acknowledges that the current stock price reflects a bubble, significantly deviating from the company's fundamentals [4][7]. - The company warns of potential risks associated with irrational market speculation, as its stock price has been influenced by market sentiment rather than underlying business performance [7][13].